Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening

W. J. Catalona, D. S. Smith, T. L. Ratliff and J. W. Basler
Division of Urologic Surgery, Washington University School of Medicine, St Louis, MO.

OBJECTIVE--To determine whether prostate-specific antigen (PSA)-based screening alters the proportion of organ-confined prostate cancers detected. DESIGN--A prospective, nonrandomized, serial PSA-based screening trial (follow-up from 6 to 37 months), and a concurrent comparison group. SETTING--General community outpatient screening program based at a university center. PATIENTS--The study group consisted of 10,251 men aged 50 years and older (mean and median age, 63 years; mean and median age of patients who underwent biopsies, 66 years) who presented to a prostate cancer screening program and consented to phlebotomy. The comparison group consisted of 266 concurrently studied private patients in the same age range (mean and median age, 68 years) who were referred for prostatic ultrasonography and biopsy because of an abnormal digital rectal examination (DRE). MAIN OUTCOME MEASURE--Proportion detected with clinically or pathologically advanced prostate cancer. RESULTS--The men were divided into three groups: the comparison group, the initial PSA-based screening group, and the serial PSA-based screening group. The proportions of prostate cancers detected that were clinically or pathologically advanced were as follows: comparison group, 57% (27/47); initial PSA-based screening group, 37% (91/244); and serial PSA-based screening group, 29% (37/129). Screened patients had a lower proportion of advanced cancers than the comparison group (chi 2 [2] = 12.3; P = .002); this advantage was observed principally in patients younger than 70 years. Surgical staging revealed that the cancer was microscopically focal and well differentiated (possibly latent cancer) in 2.5% (1/40) of the nonscreened group, 2.9% (7/244) of the initially screened group, and 7.8% (10/129) of the serially screened group (generalized Fisher's Exact Test, P = .08). CONCLUSION--Screening based on PSA identifies some men with prostate cancer who have a significantly increased proportion of organ-confined tumors compared with those detected through evaluation for an abnormal DRE alone.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Targeting Pelvic Lymph Nodes in Men With Intermediate- and High-Risk Prostate Cancer Despite Two Negative Randomized Trials
Nguyen and D'Amico
JCO 2008;26:2055-2056.
FULL TEXT  

What to Do with an Abnormal PSA Test
Loeb and Catalona
The Oncologist 2008;13:299-305.
ABSTRACT | FULL TEXT  

PET Imaging of VPAC1 Expression in Experimental and Spontaneous Prostate Cancer
Zhang et al.
JNM 2008;49:112-121.
ABSTRACT | FULL TEXT  

Prostate-specific antigen in the early detection of prostate cancer
Thompson and Ankerst
CMAJ 2007;176:1853-1858.
ABSTRACT | FULL TEXT  

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran
Safarinejad
Ann Oncol 2006;17:1166-1171.
ABSTRACT | FULL TEXT  

Viewpoint: expanding prostate cancer screening.
Catalona et al.
ANN INTERN MED 2006;144:441-443.
ABSTRACT | FULL TEXT  

Prediction of Organ-confined Prostate Cancer: Incremental Value of MR Imaging and MR Spectroscopic Imaging to Staging Nomograms
Wang et al.
Radiology 2005;0:2382041905.
ABSTRACT | FULL TEXT  

Pretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy
D'Amico et al.
JAMA 2005;294:440-447.
ABSTRACT | FULL TEXT  

Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or Lower
Thompson et al.
JAMA 2005;294:66-70.
ABSTRACT | FULL TEXT  

Improved Detection of Prostate Cancer Using Classification and Regression Tree Analysis
Garzotto et al.
JCO 2005;23:4322-4329.
ABSTRACT | FULL TEXT  

20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer
Albertsen et al.
JAMA 2005;293:2095-2101.
ABSTRACT | FULL TEXT  

The T Cell Receptor {gamma} Chain Alternate Reading Frame Protein (TARP), a Prostate-specific Protein Localized in Mitochondria
Maeda et al.
J. Biol. Chem. 2004;279:24561-24568.
ABSTRACT | FULL TEXT  

Prostate-Specific Antigen Doubling Time as a Surrogate Marker for Evaluation of Oncologic Drugs to Treat Prostate Cancer
Kelloff et al.
Clin. Cancer Res. 2004;10:3927-3933.
FULL TEXT  

Second Round Results of the Finnish Population-Based Prostate Cancer Screening Trial
Makinen et al.
Clin. Cancer Res. 2004;10:2231-2236.
ABSTRACT | FULL TEXT  

Comprehensive Assessment of Candidate Genes and Serological Markers for the Detection of Prostate Cancer
Nam et al.
Cancer Epidemiol. Biomarkers Prev. 2003;12:1429-1437.
ABSTRACT | FULL TEXT  

Effect of Verification Bias on Screening for Prostate Cancer by Measurement of Prostate-Specific Antigen
Punglia et al.
NEJM 2003;349:335-342.
ABSTRACT | FULL TEXT  

Verification Bias and the Prostate-Specific Antigen Test -- Is There a Case for a Lower Threshold for Biopsy?
Schroder and Kranse
NEJM 2003;349:393-395.
FULL TEXT  

Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate Cancer
Draisma et al.
JNCI J Natl Cancer Inst 2003;95:868-878.
ABSTRACT | FULL TEXT  

Single Nucleotide Polymorphism of the Human Kallikrein-2 Gene Highly Correlates With Serum Human Kallikrein-2 Levels and in Combination Enhances Prostate Cancer Detection
Nam et al.
JCO 2003;21:2312-2319.
ABSTRACT | FULL TEXT  

Cancer-Specific Mortality After Surgery or Radiation for Patients With Clinically Localized Prostate Cancer Managed During the Prostate-Specific Antigen Era
D'Amico et al.
JCO 2003;21:2163-2172.
ABSTRACT | FULL TEXT  

Management of High-Risk Populations with Locally Advanced Prostate Cancer
Khan and Partin
The Oncologist 2003;8:259-269.
ABSTRACT | FULL TEXT  

Should Routine Screening for Prostate-Specific Antigen Be Recommended?
Oottamasathien and Crawford
Arch Intern Med 2003;163:661-663.
FULL TEXT  

Biology of Prostate-Specific Antigen
Balk et al.
JCO 2003;21:383-391.
ABSTRACT | FULL TEXT  

Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity
Coldman et al.
CMAJ 2003;168:31-35.
ABSTRACT | FULL TEXT  

Ligand-independent Activation of the Androgen Receptor by Interleukin-6 and the Role of Steroid Receptor Coactivator-1 in Prostate Cancer Cells
Ueda et al.
J. Biol. Chem. 2002;277:38087-38094.
ABSTRACT | FULL TEXT  

Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis in Androgen-independent Human Prostate Cancer Cell Lines
Kim et al.
Cancer Res. 2002;62:5365-5369.
ABSTRACT | FULL TEXT  

Measurement of Prostate-specific Antigen by Use of a Novel Blood Collection and Analytical System
Grzeda et al.
Clin. Chem. 2002;48:1272-1278.
ABSTRACT | FULL TEXT  

Family History and Prostate Cancer Screening With Prostate-Specific Antigen
Makinen et al.
JCO 2002;20:2658-2663.
ABSTRACT | FULL TEXT  

Prevalence-corrected Prostate Cancer Incidence Rates and Trends
Merrill and Morris
Am J Epidemiol 2002;155:148-152.
ABSTRACT | FULL TEXT  

Diagnostic Approach to Prostate Cancer using Total Prostate Specific Antigen-Based Parameters Together
Serdar et al.
Annals of Clinical & Laboratory Science 2002;32:22-30.
ABSTRACT | FULL TEXT  

Analysis of Gene Expression Identifies Candidate Markers and Pharmacological Targets in Prostate Cancer
Welsh et al.
Cancer Res. 2001;61:5974-5978.
ABSTRACT | FULL TEXT  

Changing Relationship Between Socioeconomic Status and Prostate Cancer Incidence
Liu et al.
JNCI J Natl Cancer Inst 2001;93:705-709.
ABSTRACT | FULL TEXT  

What Questions Do Families of Patients With Early-Stage Prostate Cancer Want Answered?
Feldman-Stewart et al.
Journal of Family Nursing 2001;7:188-207.
ABSTRACT  

Prostate Cancer: Contrast-enhanced US for Detection
Halpern et al.
Radiology 2001;219:219-225.
ABSTRACT | FULL TEXT  

Molecular Cytogenetic Analysis of Prostatic Adenocarcinomas from Screening Studies : Early Cancers May Contain Aggressive Genetic Features
Alers et al.
Am. J. Pathol. 2001;158:399-406.
ABSTRACT | FULL TEXT  

Prostate Cancer: What Is the Future Role for Imaging?
Thornbury et al.
Am. J. Roentgenol. 2001;176:17-22.
FULL TEXT  

Molecular Forms of Prostate-specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer
Stephan et al.
Cancer Epidemiol. Biomarkers Prev. 2000;9:1133-1147.
ABSTRACT | FULL TEXT  

Ligand-independent Activation of the Androgen Receptor by the Differentiation Agent Butyrate in Human Prostate Cancer Cells
Sadar and Gleave
Cancer Res. 2000;60:5825-5831.
ABSTRACT | FULL TEXT  

Antagonists of Growth Hormone-Releasing Hormone and Vasoactive Intestinal Peptide Inhibit Tumor Proliferation by Different Mechanisms: Evidence from in Vitro Studies on Human Prostatic and Pancreatic Cancers
Rekasi et al.
Endocrinology 2000;141:2120-2128.
ABSTRACT | FULL TEXT  

Dual-Label Time-resolved Immunofluorometric Assay of Free and Total Prostate-specific Antigen Based on Recombinant Fab Fragments
Eriksson et al.
Clin. Chem. 2000;46:658-666.
ABSTRACT | FULL TEXT  

Interleukin 8 Expression Regulates Tumorigenicity and Metastases in Androgen-independent Prostate Cancer
Inoue et al.
Clin. Cancer Res. 2000;6:2104-2119.
ABSTRACT | FULL TEXT  

Serum Human Glandular Kallikrein-2 Protease Levels Predict the Presence of Prostate Cancer Among Men With Elevated Prostate-Specific Antigen
Nam et al.
JCO 2000;18:1036-1036.
ABSTRACT | FULL TEXT  

What Questions Do Patients with Curable Prostate Cancer Want Answered?
Feldman-Stewart et al.
Med Decis Making 2000;20:7-19.
ABSTRACT  

Treatment of Locally Advanced Prostate Cancer: Is Chemotherapy the Next Step?
Oh and Kantoff
JCO 1999;17:3664-3675.
ABSTRACT | FULL TEXT  

Caveolin-1 Expression in Clinically Confined Human Prostate Cancer: A Novel Prognostic Marker
Yang et al.
Cancer Res. 1999;59:5719-5723.
ABSTRACT | FULL TEXT  

Declining Rates of Extracapsular Extension After Radical Prostatectomy: Evidence for Continued Stage Migration
Jhaveri et al.
JCO 1999;17:3167-3172.
ABSTRACT | FULL TEXT  

Cancer Surveillance Series: Interpreting Trends in Prostate Cancer—Part II: Cause of Death Misclassification and the Recent Rise and Fall in Prostate Cancer Mortality
Feuer et al.
JNCI J Natl Cancer Inst 1999;91:1025-1032.
ABSTRACT | FULL TEXT  

Cancer Surveillance Series: Interpreting Trends in Prostate Cancer—Part III: Quantifying the Link Between Population Prostate-Specific Antigen Testing and Recent Declines in Prostate Cancer Mortality
Etzioni et al.
JNCI J Natl Cancer Inst 1999;91:1033-1039.
ABSTRACT | FULL TEXT  

Detection of Subclinical Cancers by Prostate-specific Antigen Screening in Asymptomatic Men from High-Risk Prostate Cancer Families
Matikainen et al.
Clin. Cancer Res. 1999;5:1275-1279.
ABSTRACT | FULL TEXT  

Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer
Albertsen et al.
JAMA 1998;280:975-980.
ABSTRACT | FULL TEXT  

Androgenic Induction of Prostate-specific Antigen Gene Is Repressed by Protein-Protein Interaction between the Androgen Receptor and AP-1/c-Jun in the Human Prostate Cancer Cell Line LNCaP
Sato et al.
J. Biol. Chem. 1997;272:17485-17494.
ABSTRACT | FULL TEXT  

Analytical performance of the Tandem(R)-R free PSA immunoassay measuring free prostate-specific antigen
Woodrum et al.
Clin. Chem. 1997;43:1203-1208.
ABSTRACT | FULL TEXT  

The role of motility proteins and metastasis-suppressor genes in prostate cancer progression
Rinker-Schaeffer et al.
Stem Cells 1996;14:508-516.
ABSTRACT  

Screening for Prostate Cancer with Prostate-Specific Antigen -- An Examination of the Evidence
Woolf
NEJM 1995;333:1401-1405.
FULL TEXT  

Preventive Health Services
Catalona et al.
NEJM 1994;331:1156-1158.
FULL TEXT  

Management of Cancer of the Prostate
Catalona
NEJM 1994;331:996-1004.
FULL TEXT